市場調查報告書
商品編碼
1370641
粒子治療市場-按類型(質子、重離子)、副產品(同步加速器、迴旋加速器)、按服務、按系統(多室系統、單室系統)、按癌症類型(小兒癌、肺癌、膀胱癌、乳腺癌症)及預測,2023-2032Particle Therapy Market-By Type (Proton, Heavy Ion), By Product (Synchrotrons, Cyclotrons), By Services, By System (Multi-Room Systems, Single-Room Systems), By Cancer Type (Pediatric Cancer, Lung Cancer, Bladder, Breast Cancer) & Forecast, 2023-2032 |
2023 年至 2032 年間,全球粒子治療市場的年複合成長率將超過 8.7%。由於領先的醫院和醫療機構擴大採用尖端粒子治療設備,預計該市場將蓬勃發展。例如,2023 年 9 月,粒子加速器技術的全球領導者和癌症治療質子治療解決方案的領先供應商 ION Beam Applications SA (IBA) 與 Medtechnica Ltd 正式簽署了最終協議。該協議為在以色列特拉維夫的Sourasky 醫療中心(也稱為Ichilov 醫院)安裝了兩台最先進的Proteus (R)ONE 緊湊型質子治療系統。
這些醫院正在選擇頂級製造商的優質設備,這反過來又推動了粒子治療市場的成長。粒子療法精確且有效的治療能力是這一趨勢的關鍵因素,因為醫療保健提供者力求為患者提供最佳的護理。
整個粒子治療市場根據產品、癌症類型和地區進行分類。
迴旋加速器領域將在 2023 年至 2032 年間經歷重大發展。迴旋加速器透過將這些粒子加速到精確的能量以實現有效的治療,從而在癌症治療中發揮關鍵作用。隨著醫學界越來越認知到粒子治療的精確度和益處,對迴旋加速器的需求不斷增加,支撐了粒子治療的市場前景。由於上述原因,對迴旋加速器的需求正在快速成長,迴旋加速器是生產質子和重離子治療所需粒子的重要組成部分。
2023年至2032年,兒科癌症領域將出現顯著的年複合成長率。粒子療法,包括質子和重離子療法,因其精確性和副作用減少而受到關注,使其成為年輕癌症患者的理想選擇。隨著人們對粒子療法在治療兒童癌症方面的優勢的認知不斷增強,這一專業領域的粒子療法市場需求正在增加。
亞太地區粒子治療市場將於 2023 年至 2032 年呈現可觀的年複合成長率。人口成長、癌症發病率增加以及對粒子治療益處的更多認知等因素正在推動這一需求。亞洲國家正在擴大其醫療基礎設施,包括質子和重離子治療設施,這顯示亞太地區的市場成長軌跡顯著。例如,2023 年 10 月,日立有限公司和日立亞洲有限公司在一份聯合聲明中披露,已成功向新加坡國家癌症中心(「NCCS」)交付質子治療系統。這項成就標誌著日立首個質子治療系統在東南亞用於病患治療的開創性時刻。
Global Particle Therapy Market will witness over 8.7% CAGR between 2023 and 2032. The market is expected to flourish due to the increasing adoption of cutting-edge particle therapy equipment by leading hospitals and health facilities. For instance, in September 2023, ION Beam Applications S.A. (IBA), a global frontrunner in particle accelerator technology and the foremost provider of proton therapy solutions for cancer treatment, officially inked the conclusive agreement with Medtechnica Ltd. This agreement paves the way for the installation of two state-of-the-art Proteus®ONE compact proton therapy systems at the Sourasky Medical Center, also known as Ichilov Hospital, in Tel Aviv, Israel.
These hospitals are choosing high-quality equipment from top manufacturers, which, in turn, fuels the particle therapy market growth. The precise and effective treatment capabilities of particle therapy are a key factor in this trend, as healthcare providers seek to offer the best possible care to their patients.
The overall Particle Therapy Market is classified based on product, cancer type, and region.
Cyclotrons segment will undergo significant development from 2023 to 2032. Cyclotrons play a pivotal role in cancer treatment by accelerating these particles to precise energies for effective therapies. As the medical community increasingly recognizes the precision and benefits of particle therapy, the demand for cyclotrons is on the rise, supporting the particle therapy market outlook. The demand for cyclotrons, which are integral in producing the necessary particles for proton and heavy ion therapy, is registering high growth due to the above-stated reasons.
The pediatric cancer segment will register a notable CAGR from 2023 to 2032. Particle therapy, including proton and heavy ion therapy, is gaining prominence for its precision and reduced side effects, making it an ideal choice for young cancer patients. As awareness grows about the advantages of particle therapy in treating pediatric cancers, the particle therapy market demand in this specialized field is on the rise.
Asia Pacific particle therapy market will showcase an appreciable CAGR from 2023 to 2032. Factors such as a growing population, increasing cancer incidence, and a greater awareness of the benefits of particle therapy are driving this demand. Asian countries are expanding their healthcare infrastructure to include proton and heavy ion therapy facilities, indicating a significant market growth trajectory in the Asia Pacific. For instance, in October 2023, in a joint statement, Hitachi, Ltd. and Hitachi Asia Ltd. disclosed the successful delivery of a proton therapy system to the National Cancer Centre Singapore ("NCCS"). This achievement marks a groundbreaking moment as Hitachi's inaugural proton therapy system to be operational for patient treatment in Southeast Asia.